[]

FORM 4

obligations may continue. See Instruction 1(b).

Check this box if no longer subject to Section 16. Form 4 or Form 5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden

0.5

hours per response:

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 20(b) of the Investment Company Act of 1040

1. Name and Address	1 0	on [*]	2. Issuer Name and Ticker or Trading Symbol Kymera Therapeutics, Inc. [KYMR]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
<u>Mainolfi Nello</u>	<u>)</u>			X	Director	10% Owner				
(Last) C/O KYMERA T 200 ARSENAL Y		1. Alt	3. Date of Earliest Transaction (Month/Day/Year) 05/12/2021	x	Officer (give title below) Chief Executive	Other (specify below) Officer				
(Street) WATERTOWN (City)	MA (State)	02472 (Zip)	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line) X	idual or Joint/Group Filing Form filed by One Repo Form filed by More than Person	orting Person				
Table I - Non-Derivative Securities Acquired. Disposed of, or Beneficially Owned										

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)						6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)
Common Stock	05/12/2021		М		8,245	A	\$2.08	405,444	D	
Common Stock	05/12/2021		S ⁽¹⁾		8,245	D	\$50.0518 ⁽²⁾	397,199	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		n of		6. Date Exerc Expiration Da (Month/Day/Y	ate	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	\$2.08	05/12/2021		М			8,245	(3)	11/13/2029	Common Stock	8,245	\$0.00	216,480	D	

Explanation of Responses:

1. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020.

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$50.00 to \$50.29. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

3. The shares underlying this stock option shall vest upon the achievement of specified performance-based milestones.

Remarks:

/s/ Bruce Jacobs, as Attorney-<u>in-Fact</u> 05/14/2021

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.